Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology

The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on in...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Vittorio Fusco, Giuseppina Campisi, Paul de Boissieu, Federico Monaco, Anna Baraldi, Gianmauro Numico, Alberto Bedogni
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI AG 2018-09-01
Seri Bilgileri:Dentistry Journal
Konular:
osteonecrosis of the jaw
ONJ
osteonecrosis
jaw
medication-related osteonecrosis of the jaw
MRONJ
multiple myeloma
denosumab
zoledronic acid
Online Erişim:http://www.mdpi.com/2304-6767/6/3/42
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller